4CMenB Vaccine

Benefits

Dosage & preparation

Evidence quality

Where it comes from

Other

Highlighted claims

• 4CMenB is an FDA-approved four-component MenB vaccine sold under the trade name Bexsero. — Efficacy of the serogroup B Neisseria meningitidis vaccine (4CMenB) in preventing experimental Neisseria gonorrhoeae urethral infection: a double-blind randomised controlled human challenge study protocol
• 4CMenB contains NmB outer membrane vesicles and recombinant proteins including fHbp, NHBA, NadA, GNA2091, and GNA1030. — Efficacy of the serogroup B Neisseria meningitidis vaccine (4CMenB) in preventing experimental Neisseria gonorrhoeae urethral infection: a double-blind randomised controlled human challenge study protocol
• The trial uses two intramuscular doses of 4CMenB given at least 28 days apart. — Efficacy of the serogroup B Neisseria meningitidis vaccine (4CMenB) in preventing experimental Neisseria gonorrhoeae urethral infection: a double-blind randomised controlled human challenge study protocol
• The evidence from retrospective 4CMenB studies has limitations because it relied on symptomatic clinic data and could not separate infection prevention from symptom attenuation. — Efficacy of the serogroup B Neisseria meningitidis vaccine (4CMenB) in preventing experimental Neisseria gonorrhoeae urethral infection: a double-blind randomised controlled human challenge study protocol
• Retrospective studies in Canada, Australia, and the USA reported 30-40% declines in gonorrhea incidence after 4CMenB vaccination. — Efficacy of the serogroup B Neisseria meningitidis vaccine (4CMenB) in preventing experimental Neisseria gonorrhoeae urethral infection: a double-blind randomised controlled human challenge study protocol